Tumor-associated Macrophages Drive Spheroid Formation During Early Transcoelomic Metastasis of Ovarian Cancer

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2016 Oct 11

PMID 27721235

Citations 217

Authors

Mingzhu Yin

Xia Li

Shu Tan

Huanjiao Jenny Zhou

Weidong Ji

Stefania Bellone

Xiaocao Xu

Haifeng Zhang

Alessandro D Santin

Ge Lou

Wang Min

Affiliations

Soon will be listed here.

Abstract

Tumor-associated macrophages (TAMs) can influence ovarian cancer growth, migration, and metastasis, but the detailed mechanisms underlying ovarian cancer metastasis remain unclear. Here, we have shown a strong correlation between TAM-associated spheroids and the clinical pathology of ovarian cancer. Further, we have determined that TAMs promote spheroid formation and tumor growth at early stages of transcoelomic metastasis in an established mouse model for epithelial ovarian cancer. M2 macrophage-like TAMs were localized in the center of spheroids and secreted EGF, which upregulated αMβ2 integrin on TAMs and ICAM-1 on tumor cells to promote association between tumor cells and TAM. Moreover, EGF secreted by TAMs activated EGFR on tumor cells, which in turn upregulated VEGF/VEGFR signaling in surrounding tumor cells to support tumor cell proliferation and migration. Pharmacological blockade of EGFR or antibody neutralization of ICAM-1 in TAMs blunted spheroid formation and ovarian cancer progression in mouse models. These findings suggest that EGF secreted from TAMs plays a critical role in promoting early transcoelomic metastasis of ovarian cancer. As transcoelomic metastasis is also associated with many other cancers, such as pancreatic and colon cancers, our findings uncover a mechanism for TAM-mediated spheroid formation and provide a potential target for the treatment of ovarian cancer and other transcoelomic metastatic cancers.

Citing Articles

ZEB1 promotes the immune escape of ovarian cancer through the MCSF-CCL18 axis.

Jin Y, Li G, Xu Q, Wang X Cancer Cell Int. 2025; 25(1):95.

PMID: 40089803 DOI: 10.1186/s12935-025-03724-y.

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

Identifying macrophage-associated subtypes in patients with serous ovarian cancer and exploring potential personalized therapeutic drugs using combined single-cell and bulk RNA sequencing omics.

Teng F, Wei H, Che D, Miao K, Dong X Heliyon. 2025; 11(4):e42429.

PMID: 40028569 PMC: 11870195. DOI: 10.1016/j.heliyon.2025.e42429.

TAM-derived exosomal miR-589-3p accelerates ovarian cancer progression through BCL2L13.

Wang J, Zhu Y, He Y, Shao W J Ovarian Res. 2025; 18(1):36.

PMID: 39985077 PMC: 11846191. DOI: 10.1186/s13048-025-01618-1.

Mitophagy in gynecological malignancies: roles, advances, and therapeutic potential.

Wang J, Wang D Cell Death Discov. 2024; 10(1):488.

PMID: 39639053 PMC: 11621523. DOI: 10.1038/s41420-024-02259-x.

References

McAllister S, Weinberg R . The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16(8):717-27. PMC: 6220424. DOI: 10.1038/ncb3015. View

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C . HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011; 19(1):31-44. DOI: 10.1016/j.ccr.2010.11.009. View

Hagemann T, Wilson J, Burke F, Kulbe H, Li N, Pluddemann A . Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006; 176(8):5023-32. DOI: 10.4049/jimmunol.176.8.5023. View

Lengyel E . Ovarian cancer development and metastasis. Am J Pathol. 2010; 177(3):1053-64. PMC: 2928939. DOI: 10.2353/ajpath.2010.100105. View

Peinado H, Rafii S, Lyden D . Inflammation joins the "niche". Cancer Cell. 2008; 14(5):347-9. PMC: 2951628. DOI: 10.1016/j.ccr.2008.10.012. View

Colegio O, Chu N, Szabo A, Chu T, Rhebergen A, Jairam V . Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014; 513(7519):559-63. PMC: 4301845. DOI: 10.1038/nature13490. View

Casey R, Burleson K, Skubitz K, Pambuccian S, Oegema Jr T, Ruff L . Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol. 2001; 159(6):2071-80. PMC: 1850600. DOI: 10.1016/s0002-9440(10)63058-1. View

English D, Bellone S, Schwab C, Roque D, Lopez S, Bortolomai I . Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2014; 121(3):403-12. PMC: 4304922. DOI: 10.1002/cncr.29062. View

Bjorge L, Hakulinen J, Vintermyr O, Jarva H, Jensen T, Iversen O . Ascitic complement system in ovarian cancer. Br J Cancer. 2005; 92(5):895-905. PMC: 2361909. DOI: 10.1038/sj.bjc.6602334. View

10.

Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion L . CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475(7355):222-5. PMC: 3208506. DOI: 10.1038/nature10138. View

11.

Dusenbery K, Bellairs E, Potish R, Twiggs L, Boente M . Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Gynecol Oncol. 2005; 96(2):307-13. DOI: 10.1016/j.ygyno.2004.08.040. View

12.

Yin M, Li C, Li X, Lou G, Miao B, Liu X . Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011; 104(1):29-36. DOI: 10.1002/jso.21912. View

13.

Shield K, Riley C, Quinn M, Rice G, Ackland M, Ahmed N . Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 2007; 6:11. PMC: 1929068. DOI: 10.1186/1477-3163-6-11. View

14.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

15.

Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H . LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2010; 129(3):629-35. DOI: 10.1002/ijc.25689. View

16.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

17.

Rafehi S, Valdes Y, Bertrand M, McGee J, Prefontaine M, Sugimoto A . TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocr Relat Cancer. 2015; 23(3):147-59. DOI: 10.1530/ERC-15-0383. View

18.

Robinson-Smith T, Isaacsohn I, Mercer C, Zhou M, van Rooijen N, Husseinzadeh N . Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007; 67(12):5708-16. DOI: 10.1158/0008-5472.CAN-06-4375. View

19.

Kaplan R, Riba R, Zacharoulis S, Bramley A, Vincent L, Costa C . VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438(7069):820-7. PMC: 2945882. DOI: 10.1038/nature04186. View

20.

Huang Y, Snuderl M, Jain R . Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell. 2011; 19(1):1-2. PMC: 3037265. DOI: 10.1016/j.ccr.2011.01.005. View